Physician profile
Amy E Kim
NPI 1679872899
$2,711.77
in general payments reported to CMS, 2019-2025
25 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $78.09 · 2021: $50.71 · 2022: $303 · 2023: $945 · 2024: $629 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.71 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $499.13 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $378.87 | 2021-2024 | Myrisk |
| Novo Nordisk INC | $371.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $214.48 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $187.26 | 2019-2024 | |
| Glaxosmithkline, LLC. | $186.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.01 | 2019-2025 | Jardiance |
| Amgen INC. | $116.28 | 2019-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $107.68 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $70.55 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $50.46 | 2022-2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $44.96 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $44.11 | 2019-2020 | |
| Allergan, INC. | $35.27 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $33.45 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.63 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.29 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $22.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Abbott Laboratories | $15.04 | 2023 | Freestyle Libre |
| Supernus Pharmaceuticals, INC. | $15.04 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $14.04 | 2020 | |
| Hologic Sales and Service, LLC | $14.00 | 2021 | |
| Acella Pharmaceuticals, LLC | $13.85 | 2025 | NP Thyroid 60 |
| Dexcom, INC. | $13.24 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.